The OCT2/MATE1 Interaction Between Trifluridine, Metformin and Cimetidine: A Crossover Pharmacokinetic Study.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
28 Jun 2024
28 Jun 2024
Historique:
accepted:
30
05
2024
medline:
2
7
2024
pubmed:
2
7
2024
entrez:
1
7
2024
Statut:
aheadofprint
Résumé
Trifluridine/tipiracil, registered for the treatment of patients with metastatic gastric and colorectal cancer, is a substrate and inhibitor for the organic cation transporter 2 (OCT2) and the multidrug and toxin extrusion protein 1 (MATE1), which raises the potential for drug-drug interactions with other OCT2/MATE1 modulators. Therefore, we prospectively examined the effect of an OCT2/MATE1 inhibitor (cimetidine) and substrate (metformin) on the pharmacokinetics of trifluridine. In this three-phase crossover study, patients with metastatic colorectal or gastric cancer were sequentially treated with trifluridine/tipiracil alone (phase A), trifluridine/tipiracil concomitant with metformin (phase B) and trifluridine/tipiracil concomitant with cimetidine (phase C). The primary endpoint was the relative difference in exposure of trifluridine assessed by the area under the curve from timepoint zero to infinity. A > 30% change in exposure was considered clinically relevant. A p-value of < 0.025 was considered significant because of a Bonferroni correction. Eighteen patients were included in the analysis. Metformin did not significantly alter the exposure to trifluridine (- 12.6%; 97.5% confidence interval - 25.0, 1.8; p = 0.045). Cimetidine did alter the exposure to trifluridine significantly (+ 18.0%; 97.5% confidence interval 4.5, 33.3; p = 0.004), but this increase did not meet our threshold for clinical relevance. Metformin trough concentrations were not influenced by trifluridine/tipiracil. Our result suggests that the OCT2/MATE1 modulators cimetidine and metformin can be co-administered with trifluridine/tipiracil without clinically relevant effects on drug exposure. NL8067 (registered 04-10-2019).
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Trifluridine/tipiracil, registered for the treatment of patients with metastatic gastric and colorectal cancer, is a substrate and inhibitor for the organic cation transporter 2 (OCT2) and the multidrug and toxin extrusion protein 1 (MATE1), which raises the potential for drug-drug interactions with other OCT2/MATE1 modulators. Therefore, we prospectively examined the effect of an OCT2/MATE1 inhibitor (cimetidine) and substrate (metformin) on the pharmacokinetics of trifluridine.
METHODS
METHODS
In this three-phase crossover study, patients with metastatic colorectal or gastric cancer were sequentially treated with trifluridine/tipiracil alone (phase A), trifluridine/tipiracil concomitant with metformin (phase B) and trifluridine/tipiracil concomitant with cimetidine (phase C). The primary endpoint was the relative difference in exposure of trifluridine assessed by the area under the curve from timepoint zero to infinity. A > 30% change in exposure was considered clinically relevant. A p-value of < 0.025 was considered significant because of a Bonferroni correction.
RESULTS
RESULTS
Eighteen patients were included in the analysis. Metformin did not significantly alter the exposure to trifluridine (- 12.6%; 97.5% confidence interval - 25.0, 1.8; p = 0.045). Cimetidine did alter the exposure to trifluridine significantly (+ 18.0%; 97.5% confidence interval 4.5, 33.3; p = 0.004), but this increase did not meet our threshold for clinical relevance. Metformin trough concentrations were not influenced by trifluridine/tipiracil.
CONCLUSIONS
CONCLUSIONS
Our result suggests that the OCT2/MATE1 modulators cimetidine and metformin can be co-administered with trifluridine/tipiracil without clinically relevant effects on drug exposure.
CLINICAL TRIAL REGISTRATION
BACKGROUND
NL8067 (registered 04-10-2019).
Identifiants
pubmed: 38951433
doi: 10.1007/s40262-024-01390-3
pii: 10.1007/s40262-024-01390-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–19.
doi: 10.1056/NEJMoa1414325
pubmed: 25970050
Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023;388(18):1657–67.
doi: 10.1056/NEJMoa2214963
pubmed: 37133585
Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437–48.
doi: 10.1016/S1470-2045(18)30739-3
pubmed: 30355453
Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, et al. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer. 2006;107(6):1383–90.
doi: 10.1002/cncr.22125
pubmed: 16902987
Fukushima M, Suzuki N, Emura T, Yano S, Kazuno H, Tada Y, et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides. Biochem Pharmacol. 2000;59(10):1227–36.
doi: 10.1016/S0006-2952(00)00253-7
pubmed: 10736423
European Medicines Agency. Lonsurf summary of product characteristics. 2016. https://www.ema.europa.eu/en/documents/product-information/lonsurf-epar-product-information_en.pdf . Accessed 18 June 2024.
Lee JJ, Seraj J, Yoshida K, Mizuguchi H, Strychor S, Fiejdasz J, et al. Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry. Cancer Chemother Pharmacol. 2016;77(3):515–26.
doi: 10.1007/s00280-016-2965-2
pubmed: 26787503
pmcid: 4767595
Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency. Assessment report Lonsurf 2016. https://www.ema.europa.eu/en/documents/assessment-report/lonsurf-epar-public-assessment-report_en.pdf . Accessed 18 June 2024.
Sauzay C, White-Koning M, Hennebelle I, Deluche T, Delmas C, Imbs DC, et al. Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin. Pharmacol Res. 2016;110:89–95.
doi: 10.1016/j.phrs.2016.05.012
pubmed: 27178732
Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol. 2009;20(12):1907–12.
doi: 10.1093/annonc/mdp369
pubmed: 19713244
Lord S, Hall PS, Seymour MT. Concomitant medications in cancer patients: should we be more active in their management? Ann Oncol. 2010;21(2):430.
doi: 10.1093/annonc/mdp539
pubmed: 19940008
Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther. 2007;32(2):169–75.
doi: 10.1111/j.1365-2710.2007.00815.x
pubmed: 17381667
Suh S, Kim KW. Diabetes and cancer: cancer should be screened in routine diabetes assessment. Diabetes Metab J. 2019;43(6):733–43.
doi: 10.4093/dmj.2019.0177
pubmed: 31902143
pmcid: 6943263
Lanser DAC, Van der Kleij MBA, Veerman GDM, Steeghs N, Huitema ADR, Mathijssen RHJ, et al. Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients. Biomed Pharmacother. 2023;163: 114823.
doi: 10.1016/j.biopha.2023.114823
pubmed: 37172331
US Food and Drug Administration. Center for Drug Evaluation and Research. Lonsurf clinical pharmacology and biopharmaceutics review. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000ClinPharmR.pdf .
Schoenfeld DA. Statistical considerations for a cross-over study. http://hedwig.mgh.harvard.edu/sample_size/js/js_crossover_quant.html . Accessed 18 Jun 2024.
Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency. Guideline on the investigation of bioequivalence. 2010. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf . Accessed 18 June 2024.
Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24(7):1227–51.
doi: 10.1007/s11095-007-9254-z
pubmed: 17473959
Dumitras S, Sechaud R, Drollmann A, Pal P, Vaidyanathan S, Camenisch G, et al. Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium. Int J Clin Pharmacol Ther. 2013;51(10):771–9.
doi: 10.5414/CP201946
pubmed: 24040847
US Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. 2023. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers . Accessed 18 June 2024.
Van Cutsem E, Ohtsu A, Lopez Busto N, Kanehisa A, Fougeray R, Winkler R, et al. Time to grade ≥ 3 adverse events in pts receiving trifluridine/tipiracil (TAS-102). J Clin Oncol. 2017;35(4_Suppl.):788.
Christensen MM, Pedersen RS, Stage TB, Brasch-Andersen C, Nielsen F, Damkier P, et al. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genom. 2013;23(10):526–34.
doi: 10.1097/FPC.0b013e328364a57d
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes. 2009;58(3):745–9.
doi: 10.2337/db08-1028
pubmed: 19228809
pmcid: 2646075